Hadil Onallah, Ronen Hazan, Ran Nir-Paz, Michael J Brownstein, Joseph R Fackler, Bri'Anna Horne, Robert Hopkins, Subhendu Basu, Ortal Yerushalmy, Sivan Alkalay-Oren, Ron Braunstein, Amit Rimon, Daniel Gelman, Leron Khalifa, Karen Adler, Mohanad Abdalrhman, Shira Gelman, Eyal Katvan, Shunit Coppenhagen-Glazer, Allon Moses, Yonatan Oster, Michal Dekel, Ronen Ben-Ami, Amal Khoury, Daniel J Kedar, Suzy E Meijer, Itay Ashkenazi, Nancy Bishouty, Dafna Yahav, Eran Shostak, Gilat Livni, Mical Paul, Menachem Gross, Matityahou Ormianer, Saima Aslam, Michele Ritter, Kenneth L Urish, Ricardo M La Hoz, Ameneh Khatami, Philip N Britton, Ruby C Y Lin, Jonathan R Iredell, Aleksandra Petrovic-Fabijan, Stephanie Lynch, Pranita D Tamma, Alexandra Yamshchikov, Emil Lesho, Megan Morales, Alissa Werzen, Kapil Saharia
BACKGROUND: A growing number of compassionate phage therapy cases were reported in the last decade, with a limited number of clinical trials conducted and few unsuccessful clinical trials reported. There is only a little evidence on the role of phages in refractory infections. Our objective here was to present the largest compassionate-use single-organism/phage case series in 16 patients with non-resolving Pseudomonas aeruginosa infections. METHODS: We summarized clinical phage microbiology susceptibility data, administration protocol, clinical data, and outcomes of all cases treated with PASA16 phage...
August 8, 2023: Med